Assoc. Prof. Atakan DEMİR

Chemotherapy (Medical Oncology)

Goztepe Hospital

Make an appointment

Easy Appointment

Our physician's appointments are made by the Call Center and Live Support. You can use Live Support for your appointment request or call our Call Center at +90 549 639 3366 .

Connect to Live Support

or

Let Us Call You

Connect to Live Support

You can reach us from Live Support to make an appointment with our doctor.

Let Us Call You

For your appointment request, you can fill in the form below or call our Call Center +90 549 639 3366 .

Name and Surname

Cell Phone

E-Mail Address*

I have reviewed the in accordance with the relevant Personal Data Protection Law. Hereby, I explicitly consent to the processing of my personal data within the specified scope in Privacy Notice and to be contacted for the purpose of delivering healthcare services.

Something went wrong! CAPTCHA could not be verified. Please resubmit the form.

SPECIALTIES

Treatment Methods

Laparoscopic Gallbladder Surgery

Featured Expertise

PERSONAL INFORMATION

BIRTH PLACE / DATE

Ardahan /1979

FOREIGN LANGUAGE

English, French

E MAIL ADDRESS

[email protected]

EXPERIENCE

2025 - Currently, İstanbul/Türkiye

Memorial Göztepe Hospital

Medical Oncologist

2018 - 2025, İstanbul/Türkiye

Acıbadem Maslak Hospital

Medical Oncologist

EDUCATION

2016, Texas/Houston

MD Anderson Cancer Center

2012 - 2016, İstanbul/Türkiye

ISTANBUL UNIVERSITY CERRAHPAŞA FACULTY OF MEDICINE Internal Medicine / Medical Oncology Department SPECIALIZATION

Specialization in Medicine

2006 - 2011, İstanbul/Türkiye

Istanbul University Cerrahpaşa Faculty of Medicine Department of Internal Medicine Specialization

Specialization in Medicine

1997 - 2003, İstanbul/Türkiye

Istanbul University Cerrahpaşa Faculty of Medicine

Faculty of Medicine

SCIENTIFIC PUBLICATIONS

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
N Engl J Med.2503701. Epub 2025 Jun
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.
N Engl J Med. 2025 Mar 27;392(12):1189-1202. doi: 10.1056/NEJMoa2410858.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457.
Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment.
E.World J Surg Oncol. 2019 Mar 14;17(1):50. doi: 10.1186/s12957-019-1588-
The impact of total neo-adjuvant treatment on nonoperative management in patients with locally advanced rectal cancer: The evaluation of 66 cases.
Eur J Surg Oncol. 2020 Mar;46(3):402-409. doi: 10.1016/j.ejso.2019.07.012.
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
J Clin Oncol. 2024 Aug 20;42(24):2918-2927. doi: 10.1200/JCO.23.02736.

Translated with DeepL.com (free version)

PROFESSIONAL MEMBERSHIPS

American Society of Clinical Oncology
European Society for Medical Oncology
Turkish Medical Oncology Association

Ask for price

Fill in the form below to get pricing information.

Name and Surname

Cell Phone

Nationality *

E-Mail Address*

Your message should be 10 characters at least.

I hereby give my express consent to MEMORIAL and its affiliated companies ('MEMORIAL Healthcare Group') for sending me Commercial Electronic Messages (calls, SMS, emails, etc.) for all types of information, surveys, promotions, openings, invitations, events, and other communication efforts.